Growth & profitability
- Revenue has grown 589.9% per year over the past 5 years.
Financial health
- The company is unprofitable; at its current free-cash-flow burn it has roughly 25.0 years of cash runway.
XLO Financials Xilio Therapeutics, Inc.
6 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $44M | -$35M | 0.0% | -95.9% | -$6M | — | $138M |
| 2024 | $6M | -$58M | 0.0% | -954.9% | -$18M | — | $55M |
| 2023 | — | -$76M | — | — | -$69M | — | $45M |
| 2022 | — | -$88M | — | — | -$78M | — | $120M |
| 2021 | — | -$76M | — | — | -$82M | — | $198M |
| 2020 | — | -$55M | — | — | -$38M | — | $19M |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $13M | -$10M | 0.0% | -111.6% | -$23M | — | $150M |
| Dec '25 | $14M | $10M | 0.0% | -86.5% | -$2M | — | $138M |
| Sep '25 | $19M | -$16M | 0.0% | -10.1% | -$17M | — | $104M |
| Jun '25 | $8M | -$16M | 0.0% | -177.7% | -$15M | — | $122M |
| Mar '25 | $3M | -$13M | 0.0% | -472.7% | $29M | — | $89M |
| Dec '24 | $2M | -$13M | 0.0% | -790.5% | -$14M | — | $55M |
| Sep '24 | $2M | -$14M | 0.0% | -652.3% | -$14M | — | $61M |
| Jun '24 | $2M | -$14M | 0.0% | -623.8% | — | — | $75M |
| Mar '24 | — | -$17M | — | — | — | — | $34M |
| Dec '23 | — | -$18M | — | — | -$13M | — | $45M |
| Sep '23 | — | -$17M | — | — | -$13M | — | $60M |
| Jun '23 | — | -$19M | — | — | -$17M | — | $75M |
| Mar '23 | — | -$23M | — | — | -$25M | — | $93M |
| Dec '22 | — | -$22M | — | — | -$19M | — | $120M |
| Sep '22 | — | -$20M | — | — | -$20M | — | $139M |
| Jun '22 | — | -$25M | — | — | -$18M | — | $159M |
| Mar '22 | — | -$21M | — | — | -$21M | — | $177M |
| Dec '21 | — | -$20M | — | — | -$18M | — | $198M |
| Sep '21 | — | -$16M | — | — | -$21M | — | $100M |
| Jun '21 | — | -$23M | — | — | -$21M | — | $120M |
Valuation over time
How the market has priced XLO against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has risen from 0.9× (Dec '24) to 1.2× (Jun '26).
P/S
Frequently asked questions
Is XLO growing its revenue and profit?
Over the past 5 years, Xilio Therapeutics, Inc.'s revenue has grown 589.9% per year. These are computed facts, not advice.
How much debt does XLO have?
As of FY2025, Xilio Therapeutics, Inc. reported — of total debt against $138M of cash.
What is XLO's profit margin?
In FY2025, gross margin was —, operating margin -95.9%, and net margin -80.1%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.